Biopharmaceutical royalties buyer Royalty Pharma plc (Nasdaq:RPRX) said on Wednesday that it has entered into an agreement with biotechnology company Biogen Inc (Nasdaq:BIIB) to provide up to USD250m in research and development funding for litifilimab, a first-in-class biologic in Phase 3 trials for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
Litifilimab has demonstrated proof-of-concept and a well-tolerated safety profile in both conditions, with results published in the New England Journal of Medicine. It has the potential to be the first targeted biologic approved for CLE, a disease with no currently available treatments.
Biogen expects Phase 3 trial results between 2026 and 2027.
Under the deal, Royalty Pharma will provide funding over six quarters in exchange for regulatory milestones and mid-single-digit royalties on global sales.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA